Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Mar 19, 2019 - Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Mar 19, 2019 - The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Mar 18, 2019 - Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Mar 13, 2019 - Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Mar 04, 2019 - Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.